FDA and Office of Human Research Protection Respond to Fetal Dex Complaint
Glenn McGee, PhD
With the release of the September issue of the Journal, both the Food and Drug Administration and the Office of Human Research Protections have released letters responding to the complaints.
Blog: Bioethics.net
The September issue of The American Journal of Bioethics, presaged by such astonishing articles as "The Lesbian Drug" in Newsweek, stretched the boundaries of the Journal by engaging questions about the extraordinary implications of the social and medical debate concerning the administration of dexamethasone during pregnancy in females with congenital adrenal hyperplasia.
With the release of the September issue of the Journal, both the Food and Drug Administration and the Office of Human Research Protections have released letters responding to the complaints.
Link: A Case Study in Unethical Transgressive Bioethics, Laurence McCullough, Baylor College of Medicine
Labels: fetal dex; FDA; OHRP; bioethics; American Journal of Bioethics
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home